Terms: = Pancreatic cancer AND CgA AND Diagnosis
84 results:
1. Biomarkers in neuroendocrine neoplasms.
Zouli C; Zisimopoulou E; Chrisoulidou A
Hell J Nucl Med; 2023; 26 Suppl():44-48. PubMed ID: 37658563
[TBL] [Abstract] [Full Text] [Related]
2. [Expression and significance of INSM1 and SOX11 in pancreatic neuroendocrine tumor and solid pseudopapillary neoplasm].
Cao Z; Cen HB; Zhao JH; Mei J; Qin LZ; Liao W; Ao QL
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 55(4):575-581. PubMed ID: 37534634
[TBL] [Abstract] [Full Text] [Related]
3. EMT Molecular Signatures of pancreatic Neuroendocrine Neoplasms.
Venugopal A; Michalczyk A; Khasraw M; Ackland ML
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362433
[TBL] [Abstract] [Full Text] [Related]
4. Chromogranin A (cga) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome.
Konsek-Komorowska SJ; Pęczkowska M; Kolasińska-Ćwikła AD; Konka M; Chrapowicki E; Ćwikła JB
Med Clin (Barc); 2022 Jul; 159(2):85-89. PubMed ID: 34736622
[TBL] [Abstract] [Full Text] [Related]
5. [Expression of CD200 and INSM1 in gastrointestinal and pancreatic neuroendocrine neoplasms and its diagnostic values].
Cao Z; Cen HB; Wei JG; Qin LZ; Liao W; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2021 Oct; 50(10):1134-1138. PubMed ID: 34619866
[No Abstract] [Full Text] [Related]
6. Use of Chromogranin A for Monitoring Patients With pancreatic Neuroendocrine Neoplasms.
Yu F; Fu J; Zhang C; Wu W; Ai S; Yao X; Meng Q; Huang Y; Lu G; Wang F; Qu W
Pancreas; 2021 Jul; 50(6):882-889. PubMed ID: 34347728
[TBL] [Abstract] [Full Text] [Related]
7. mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report.
Venugopal A; Gillick-Walker J; Michalczyk A; Khasraw M; Ackland ML
BMC Gastroenterol; 2021 Apr; 21(1):194. PubMed ID: 33906633
[TBL] [Abstract] [Full Text] [Related]
8. Basics for surgeons about the immunohistochemistry role in pancreatic NETs diagnosis.
Romano L; Giuliani A; Vicentini V; Schietroma M; Carlei F
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2548-2553. PubMed ID: 33829441
[TBL] [Abstract] [Full Text] [Related]
9. Thymic Carcinoid as the First Manifestation of Multiple Endocrine Neoplasia Type 1 Syndrome: A Case Report and Review of the Literature.
Zheng M; Chen S; Qi C; Ren L; Zhen Y; Yu X; Wei L
Ann Clin Lab Sci; 2020 Nov; 50(6):825-833. PubMed ID: 33334800
[TBL] [Abstract] [Full Text] [Related]
10. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.
Hong L; Wang Y; Zhang T; Zhang C; Wang L; Wang L; Wang Z; Zhong J
Med Sci Monit; 2020 Nov; 26():e926635. PubMed ID: 33141811
[TBL] [Abstract] [Full Text] [Related]
11. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm.
Shi H; Jiang C; Zhang Q; Qi C; Yao H; Lin R
Diagn Pathol; 2020 Sep; 15(1):108. PubMed ID: 32917216
[TBL] [Abstract] [Full Text] [Related]
12. Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors.
Whitt J; Hong WS; Telange RR; Lin CP; Bibb J; Beebe DJ; Chen H; Jaskula-Sztul R
Cancer Gene Ther; 2020 Dec; 27(12):898-909. PubMed ID: 32029905
[TBL] [Abstract] [Full Text] [Related]
13. Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature.
Gaiani F; de'Angelis N; Minelli R; Kayali S; Carra MC; de'Angelis GL
Medicine (Baltimore); 2019 Sep; 98(37):e17154. PubMed ID: 31517859
[TBL] [Abstract] [Full Text] [Related]
14. Plasma Chromogranin A as a Prognostic Marker in pancreatic Ductal Adenocarcinoma.
Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
[TBL] [Abstract] [Full Text] [Related]
15. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective.
Pinto MP; Muñoz Medel M; Carrillo D; Retamal IN; Bravo ML; Valenzuela Y; Nervi B; Sánchez C; Galindo H; Ibañez C; Peña J; Balmaceda C; Madrid J; Briones J; Torres J; Nilo F; Guarda FJ; Quintana JC; Orellana P; Mondaca S; Acevedo F; Vicentini D; Cordova-Delgado M; Owen GI; Garrido M
Horm Cancer; 2019 Feb; 10(1):3-10. PubMed ID: 30465145
[TBL] [Abstract] [Full Text] [Related]
16. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract] [Full Text] [Related]
17. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis.
Rossi RE; Ciafardini C; Sciola V; Conte D; Massironi S
Pancreas; 2018; 47(10):1249-1255. PubMed ID: 30325865
[TBL] [Abstract] [Full Text] [Related]
18. The Role of the Acute Octreotide Suppression Test in Detecting Patients with Neuroendocrine Neoplasms.
Kruljac I; Vičić I; Blaslov K; Kolak Z; Benković M; Kust D; Ladika Davidović B; Tometić G; Penavić I; Dabelić N; Vazdar L; Pavić T; Vrkljan M
Neuroendocrinology; 2018; 107(3):284-291. PubMed ID: 30114698
[TBL] [Abstract] [Full Text] [Related]
19. Rectal Neuroendocrine Tumor with Synchronous pancreatic Metastasis: A Case Report.
Masuoka Y; Furukawa D; Yazawa N; Izumi H; Yamada M; Mashiko T; Saito G; Okada K; Tanaka A; Suzuki T; Sadahiro S; Hirabayashi K; Nakagohri T
Tokai J Exp Clin Med; 2018 Jul; 43(2):38-44. PubMed ID: 29961930
[TBL] [Abstract] [Full Text] [Related]
20. Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity.
Rossi RE; Rausa E; Cavalcoli F; Conte D; Massironi S
Scand J Gastroenterol; 2018; 53(7):835-842. PubMed ID: 29726295
[TBL] [Abstract] [Full Text] [Related]
[Next]
